US Patent Issued to Adenylate Therapeutics on July 15 for "Systems and methods for use of adenosine triphosphate (ATP) to relieve symptoms of COVID-19 and related infections" (New Hampshire Inventor)

ALEXANDRIA, Va., July 16 -- United States Patent no. 12,357,651, issued on July 15, was assigned to Adenylate Therapeutics LLC (Claremore, Okla.).

"Systems and methods for use of adenosine triphosphate (ATP) to relieve symptoms of COVID-19 and related infections" was invented by Edward H. Abraham (Hanover, N.H.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Treatments for SARS-CoV-2 infection, COVID-19, symptoms of COVID-19, and similar infections. Specifically, treatments for patients identified as having Acute Respiratory Distress Syndrome (ARDS), and specifically COVID-19 ARDS, and/or suffering the effects of hypoxia. The treatments include increasing a patient's naturally occurring levels of ATP, adenosi...